ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70168 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Yuyan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Temozolomide, Drug Resistance, Neoplasm, Autophagy, RNA-Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Medical Science and Technology Project of Henan Province, Henan Province Outstanding Young Talent Project in Health Science and Technology Innovation for Young and Middle-aged People.
Abstract (Originalsprache)
Background
Resistance to temozolomide (TMZ) remains is an important cause of treatment failure in patients with glioblastoma multiforme (GBM). ADAR1, as a member of the ADAR family, plays an important role in cancer progression and chemotherapy resistance. However, the mechanism by which ADAR1 regulates GBM progression and TMZ resistance is still unclear.
Methods
We first constructed stable transfected strains in which ADAR1 was knocked down and overexpressed to investigate the effect of ADAR1 on the first‐line glioma chemotherapy drug TMZ. Subsequently, we validated that ADAR1 induces autophagy activation and used autophagy inhibitors to suppress autophagy, demonstrating that ADAR1 enhances TMZ resistance through autophagy. We further knocked down p62 (SQSTM1) based on the overexpression of ADAR1, and the results showed that ADAR1 regulates selective autophagy through the p62 regulation. Finally, we demonstrated through mutations at both edited and nonedited sites that ADAR1 regulates selective autophagy in an edited dependent way.
Results
Further analysis showed that in the presence of TMZ, elevated ADAR1 promoted TMZ induced autophagy activation. Further research revealed that ADAR1 enhances TMZ resistance through p62‐mediated selective autophagy. Further, ADAR1 regulates selective autophagy in an edited dependent way. Our results indicate a relationship between ADAR1 levels and the response of glioma patients to TMZ treatment.
Conclusions
We found that the expression of ADAR1 is upregulated in GBM and is associated with tumor grade and TMZ resistance. Elevated expression of ADAR1 predicts poor prognosis in GBM patients and promotes tumor growth in vivo or in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Key Clinical Laboratory of Henan Province, Zhengzhou, Henan, China.
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Electron Microscopy Laboratory of Renal Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Weiwei Wang, Jianwei Wei
Förderung
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Medical Science and Technology Project of Henan Province
- Henan Province Outstanding Young Talent Project in Health Science and Technology Innovation for Young and Middle-aged People
- Henan Province Key Research and Development (R & D) program
- Key scientific research project plan of colleges and universities in Henan Province
- Key project of Henan Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Guo, H., Bu, J., Wang, W., Wang, L., Liu, Z., Qiu, Y., Wang, Q., Zhou, L., Liu, X., Ma, L., & Wei, J. (2025). ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70168
Vancouver
Zhang Y, Guo H, Bu J, Wang W, Wang L, Liu Z, et al. ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70168
BibTeX
@article{Zhang2025,
author = {Zhang, Yuyan and Guo, Huiling and Bu, Jiahao and Wang, Weiwei and Wang, Li and Liu, Zhibo and Qiu, Yuning and Wang, Qimeng and Zhou, Lijuan and Liu, Xianzhi and Ma, Liwei and Wei, Jianwei},
title = {ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70168}
}
EUVIMED